{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:21:26Z","timestamp":1783984886524,"version":"3.55.0"},"reference-count":112,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T00:00:00Z","timestamp":1680393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The most common driver gene mutation in patients with non\u2010small\u2010cell lung cancer (NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of EGFR\u2010tyrosine kinase inhibitors, the treatment prospects and prognosis of NSCLC patients with EGFR\u2010sensitive mutations have significantly improved. Nonetheless, therapies targeting NSCLC are still associated with a risk of primary or secondary nonclassical drug resistance mutations. In recent years, the research and methodology have led to the continuous discovery of new drugs and drug resistance targets. These explorations have also resulted in continuously discovering new drugs. Consequently, rapid advancements have been made to overcome NSCLC drug resistance. This study aimed to review the current dilemma of targeted therapy for EGFR mutation\u2010positive NSCLC and the coping strategies for these difficulties.<\/jats:p>","DOI":"10.1111\/1759-7714.14858","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T04:49:23Z","timestamp":1680497363000},"page":"1121-1134","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Precision targeted therapy for <scp>EGFR<\/scp> mutation\u2010positive <scp>NSCLC<\/scp>: Dilemmas and coping strategies"],"prefix":"10.1111","volume":"14","author":[{"given":"Ying","family":"Meng","sequence":"first","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rilan","family":"Bai","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6496-7550","authenticated-orcid":false,"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[{"name":"Cancer Center The First Hospital of Jilin University  Changchun China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000033"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904554"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1113"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.063"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.22.2566"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","unstructured":"ShiYCG WangX LiuY WuL HaoY et al.Furmonertinib versus gefitinib in treatment\u2010na\u00efve EGFR mutated non\u2010small cell lung cancer: a randomized double\u2010blind multi\u2010center phase III study (FURLONG) ELCC.2022Oral Presentation Abstract 1O.","DOI":"10.1016\/j.annonc.2022.02.010"},{"issue":"5","key":"e_1_2_9_8_1","first-page":"576","article-title":"Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M\u2010mediated resistance","volume":"4","author":"Villadolid J","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.104"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0818-2"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15036"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2022.10.006"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI160152"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6428"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.01.007"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2022.2153269"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.05.012"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.11.008"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17960"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0903"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.0c00472"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","unstructured":"SchalmSS DineenT LimSM ParkCW HsiehJ WoessnerR et al.1296P BLU\u2010945 a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M\/C797S resistant NSCLC \u2013 ScienceDirect. Annals of Oncology; 31.","DOI":"10.1016\/j.annonc.2020.08.1610"},{"key":"e_1_2_9_23_1","article-title":"Abstract 1320: Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor","volume":"79","author":"Liu X, Zhang X, Yang L, Tian X, Dong T, Ding CZ, et al.","year":"2019","journal-title":"AACR Annual Meeting"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0229"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1844801"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.05.019"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9507"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.159"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.1121"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.09.1295"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9057"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070923"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000060"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-141"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-916"},{"key":"e_1_2_9_36_1","article-title":"A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR\u2010TKIs","volume":"134","author":"Ji SP","year":"2019","journal-title":"Lung Cancer"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1915"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2246"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2969"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1022"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9009"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.292"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9006"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.1130"},{"key":"e_1_2_9_45_1","article-title":"Tepotinib plus gefitinib in patients with EGFR\u2010mutant non\u2010small\u2010cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT Study): an open\u2010label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu Y\u2010L, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, et al.","year":"2020","journal-title":"Lancet Respir Med"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.7326"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30785-5"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.146"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9119"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1844"},{"key":"e_1_2_9_51_1","unstructured":"Abatract MA02.06 ZhangL ZhaoH MaY ChengY ZhaoY CuiJ et al.Phase 1b study of pelcitoclax (APG\u20101252) in combination with osimertinib inpatients with EGFR\u2010TKI\u2010resistant NSCLC.2021World Conference on Lung Cancer."},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0628"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.006"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30634-5"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08074-0"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2648"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.09.457"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3990"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35962-x"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.063"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32503"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010006"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13521"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31774-X"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.07.013"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051115"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1090-x"},{"key":"e_1_2_9_69_1","doi-asserted-by":"crossref","unstructured":"JebbinkM LangenA MonkhorstK BoelensMC BroekD NoortV et al.MA02.07 T\u2010DM1 and osimertinib (TRAEMOS) to target HER2 bypass track resistance in EGFRm+ NSCLC: Interim analysis of a phase II trial.2021.","DOI":"10.1016\/j.jtho.2021.08.116"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9504"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510"},{"key":"e_1_2_9_74_1","first-page":"66","article-title":"ASCO 2020 Non\u2010small lung cancer (NSCLC) personal highlights","volume":"14","author":"Horvath L","year":"2021","journal-title":"Memory"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1745"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0517-4"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0452"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-5192"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0779-5"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02549"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2554"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0510-9"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30144-X"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30160-8"},{"issue":"6","key":"e_1_2_9_86_1","first-page":"27","article-title":"Phase 1\/2 study of the safety and clinical activity of durvalumab in patients with non\u2010small cell lung cancer (NSCLC)","author":"Antonia SJ","year":"2016","journal-title":"Ann Oncol"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.016"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1073-4"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29"},{"key":"e_1_2_9_90_1","doi-asserted-by":"crossref","unstructured":"NogamiAN BarlesiBF MasC ReckDM CatE CappuzzoFF et al.IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.2021.","DOI":"10.1016\/j.jtho.2021.09.014"},{"key":"e_1_2_9_91_1","doi-asserted-by":"crossref","unstructured":"LuS WuL JianH ChengY WangQ FangJ et al.VP9\u20102021: ORIENT\u201031: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR\u2010TKI therapy.2022.","DOI":"10.1016\/j.annonc.2021.10.007"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03898-1"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26806-7"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-388"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182779d18"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.019"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.007"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007205"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2009.12.010"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0007-9"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26276"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.019"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9514"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13931"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1683"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2020.11.007"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06814-w"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0020-5"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature18621"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.10.006"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00365-x"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1080\/03639045.2020.1822860"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01681-y"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:15:25Z","timestamp":1692724525000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.14858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,2]]},"references-count":112,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/1759-7714.14858"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.14858","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,2]]},"assertion":[{"value":"2023-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}